Hidradenitis Suppurativa in the United States: Insights From the National Inpatient Sample (2008-2017) on Contemporary Trends in Demographics, Hospitalization Rates, Chronic Comorbid Conditions, and Mortality.

comorbidities hidradenitis suppurativa hs hospitalizations length of stay mortality

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
May 2022
Historique:
accepted: 05 05 2022
entrez: 10 6 2022
pubmed: 11 6 2022
medline: 11 6 2022
Statut: epublish

Résumé

Background Hidradenitis suppurativa (HS) is a clinical condition characterized by the formation of painful lumps under the skin. It often affects intertriginous areas like armpits and groin. There is a paucity of contemporary data on patient and hospital-level characteristics of HS in the United States. Methods We analyzed the Nationwide Inpatient Sample (NIS) for retrospective analysis to calculate the frequency and yearly rates of HS hospitalizations, demographic variations, rates of comorbidities, and length of stay. Results The rate of hospitalizations with HS as a primary diagnosis increased from 7.9 per 100,000 all-cause hospitalizations in 2008 to 11.6 per 100,000 all-cause hospitalizations in 2017 (p < 0.0001). The mean age ± standard error of hospitalized patients was 39.5 ± 0.2 years. The age group of 18-34 years was the most affected. Women showed a higher preponderance of the disease than men (56.6% vs. 43.5%, p < 0.0001). The Black race was the most affected out of all the racial groups (59.9%). Most hospitalizations were in large, urban teaching hospitals. Hypertension (34.9%), skin and subcutaneous tissue infections (26.5%), and diabetes mellitus (25.9%) were the most common comorbidities. Out of the total hospitalizations with HS, 12.7% were found to have a major or extreme loss of function and 3.5% were at a major or extreme likelihood of dying. Conclusions HS disproportionately affects young adults, women, and Black patients. A significant proportion of these patients are at a major risk of major loss of bodily function or death. Prospective studies are needed to identify the risk factors for hospitalizations in these patient populations and devise appropriate prevention and treatment strategies.

Identifiants

pubmed: 35686277
doi: 10.7759/cureus.24755
pmc: PMC9170363
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e24755

Informations de copyright

Copyright © 2022, Patel et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

J Cutan Med Surg. 2021 Mar-Apr;25(2):177-187
pubmed: 33174482
Dermatology. 2014;229(2):154-8
pubmed: 25228133
Int J Womens Dermatol. 2020 Feb 19;6(2):85-88
pubmed: 32258337
J Am Acad Dermatol. 2020 Feb;82(2):510-513
pubmed: 31541745
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):50-61
pubmed: 32460374
Front Immunol. 2018 Dec 14;9:2965
pubmed: 30619323
J Clin Aesthet Dermatol. 2018 Oct;11(10):17-23
pubmed: 30519375
Dermatol Ther (Heidelb). 2020 Feb;10(1):63-71
pubmed: 31955366
J Fam Pract. 2000 Feb;49(2):147-52
pubmed: 10718692
Dermatoendocrinol. 2010 Jan;2(1):9-16
pubmed: 21547142
J Am Acad Dermatol. 2020 Feb;82(2):366-376
pubmed: 31279015
Dermatology. 2017;233(6):456-461
pubmed: 29495009
Int J Dermatol. 2021 Nov;60(11):e449-e458
pubmed: 33890304
Dermatology. 2016;232(5):613-618
pubmed: 27684441
SAGE Open Med. 2021 Jun 03;9:20503121211022996
pubmed: 34158942
Int J Womens Dermatol. 2021 Oct 29;7(5Part B):664-671
pubmed: 35028361
Dermatology. 2020;236(5):439-444
pubmed: 31927547
JAMA Dermatol. 2018 Sep 1;154(9):1086-1088
pubmed: 30073254
J Am Acad Dermatol. 2018 Jul;79(1):71-76
pubmed: 29339240
JAMA. 2017 Nov 28;318(20):2019-2032
pubmed: 29183082
J Cutan Aesthet Surg. 2017 Apr-Jun;10(2):95-100
pubmed: 28852296
J Am Acad Dermatol. 2012 Sep;67(3):422-8, 428.e1
pubmed: 22182915
Acta Derm Venereol. 2011 May;91(3):328-32
pubmed: 21394419
Gastroenterology Res. 2021 Apr;14(2):87-95
pubmed: 34007350
F1000Res. 2017 Jul 28;6:1272
pubmed: 28794864
JACC Cardiovasc Interv. 2017 Oct 23;10(20):2050-2060
pubmed: 29050621
Best Pract Res Clin Obstet Gynaecol. 2014 Oct;28(7):1013-27
pubmed: 25214437
Skin Appendage Disord. 2016 Feb;1(3):117-22
pubmed: 27171648
Can Fam Physician. 2017 Feb;63(2):114-120
pubmed: 28209676
J Am Acad Dermatol. 2019 Oct;81(4):937-942
pubmed: 31202872
Dermatology. 2015;231(2):184-90
pubmed: 26139027
Ther Adv Chronic Dis. 2021 Nov 23;12:20406223211055920
pubmed: 34840709
Front Immunol. 2019 Apr 25;10:892
pubmed: 31105704
J Am Acad Dermatol. 2013 Mar;68(3):412-9
pubmed: 22921795
JAMA Dermatol. 2017 Aug 1;153(8):760-764
pubmed: 28492923
BMJ Open. 2019 Sep 30;9(9):e030579
pubmed: 31575575

Auteurs

Amie Patel (A)

Medicine, New York Institute of Technology College of Osteopathic Medicine, Old Westbury, USA.

Anjali Patel (A)

Medicine, University of Texas at Austin, Austin, USA.

Dhanshree Solanki (D)

Hospital Administration, Rutgers University, New Brunswick, USA.

Uvesh Mansuri (U)

Medicine, MedStar Good Samaritan Hospital, Baltimore, USA.

Aanandita Singh (A)

Medicine, Sri Guru Ram Das Institute of Medical Sciences & Research, Amritsar, IND.

Purnima Sharma (P)

Medicine, Texas Tech University Health Sciences Center, El Paso, USA.

Shantanu Solanki (S)

Hospital-Based Medicine, Independent Researcher, Hoboken, USA.

Classifications MeSH